Related Experiment Video
Updated: Jul 18, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer
Beth Gustafson1, Lindsey Douglass1, Timothy Pluard1
1Saint Luke's Cancer Institute.
Abstract:
Next-generation sequencing (NGS) identifies biomarkers with prognostic and predictive importance in patients with cancer. The enormous amounts of data generated by comprehensive NGS adds complexity to the identification of valid drug therapy targets. Rapid progress made in targeted drug development creates the need for novel methods to access these treatments for patients. Molecular tumor boards (MTB) not only aid in identifying targetable gene mutations by carefully reviewing NGS data, they can also take lead in creating patient access to the appropriate targeted therapy. Here we describe two patients with Kirsten Rat Sarcoma (KRAS) G12C mutation positive lung adenocarcinoma for whom MTB was able to procure AMG510 or sotorasib, a covalent KRAS G12C inhibitor, by expanded access program ahead of FDA approval.
Insights
Molecular tumor boards (MTBs) facilitate access to targeted cancer therapies by analyzing next-generation sequencing (NGS) data. This enabled two lung adenocarcinoma patients with KRAS G12C mutations to receive sotorasib via an expanded access program.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Next-generation sequencing (NGS) generates vast amounts of data, complicating the identification of actionable targets for cancer therapy.
- Targeted drug development is rapidly advancing, necessitating efficient patient access to novel treatments.
- Molecular tumor boards (MTBs) play a crucial role in interpreting complex genomic data and facilitating treatment access.
Purpose of the Study:
- To illustrate the role of Molecular Tumor Boards (MTBs) in identifying targetable mutations and securing patient access to novel therapies.
- To describe the successful procurement of AMG510 (sotorasib) for patients with KRAS G12C-mutated lung adenocarcinoma through an expanded access program.
Main Methods:
- Comprehensive next-generation sequencing (NGS) analysis of tumor tissue.
- Multidisciplinary review of genomic data by a Molecular Tumor Board (MTB).
- Utilizing an expanded access program to obtain investigational therapy (AMG510/sotorasib) prior to regulatory approval.
Main Results:
- Identification of the KRAS G12C mutation in two patients with lung adenocarcinoma.
- MTB facilitated the process of patient eligibility and application for the expanded access program.
- Successful procurement and administration of AMG510 (sotorasib) to both patients.
Conclusions:
- MTBs are instrumental in translating complex NGS findings into clinical action, particularly for rare or novel mutations.
- Expanded access programs, guided by MTBs, can provide timely access to promising targeted therapies for patients with limited options.
- The KRAS G12C inhibitor sotorasib shows potential for treating lung adenocarcinoma harboring this specific mutation.
